Decreased half life of cyclophosphamide in patients under continual treatment.
about
Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients.Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolismDisposition of antipyrine in African patients with Hodgkin's lymphomaPhase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
P2860
Decreased half life of cyclophosphamide in patients under continual treatment.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
Decreased half life of cyclophosphamide in patients under continual treatment.
@en
type
label
Decreased half life of cyclophosphamide in patients under continual treatment.
@en
prefLabel
Decreased half life of cyclophosphamide in patients under continual treatment.
@en
P2093
P1476
Decreased half life of cyclophosphamide in patients under continual treatment.
@en
P2093
D'Incalci M
Facchinetti T
Mangioni C
Morazzoni P
P356
10.1016/0014-2964(79)90198-1
P577
1979-01-01T00:00:00Z